Abstract: Slide Presentations |

Current Activity of Ceftriaxone Among Streptococcus pneumoniae in Hospital and Community Patients in 2003-2004 FREE TO VIEW

James A. Karlowsky, PhD; Mark E. Jones, PhD*; Deborah C. Draghi, BS; Ronald N. Master, MS; Daniel F. Sahm, PhS
Author and Funding Information

Focus Technologies, Inc., Herndon, VA


Chest. 2004;126(4_MeetingAbstracts):737S. doi:10.1378/chest.126.4_MeetingAbstracts.737S-a
Text Size: A A A
Published online


PURPOSE:  Streptococcus pneumoniae (SP) is the most common n isolated from hospitalized patients with community-acquired pneumonia (CAP). SP resistant to penicillin and macrolides are increasingly common, and the emerging specter of multiple drug resistance (MDR; 32 drug resistant to penicillin, cefuroxime, erythromycin, tetracycline, or trimethoprim-sulfamethoxazole as previously defined by the U.S. FDA) is cause for concern. We reviewed the current activity of ceftriaxone, a well-established agent in treating CAP from 2003/4isolates.

METHODS:  We analyzed susceptibility data (Jan 2003 to Feb 2004) from TSN, a database containing routine results from >300 microbiology labs in the US. Results for a total of 4947 S. pneumoniae (SP) collected from LRTIs tested against ceftriaxone (CTX), and comparator agents used to define MDR phenotypes were considered. Analysis considered outpatient (OP), inpatient (IP), or intensive care unit (ICU) status. NCCLS (2004) methodology and breakpoints were applied.

RESULTS:  Resistance in SP from OP, IP, and ICU was respectively 17.8, 16.4 and 17.7% for penicillin (PEN), 32.9, 33.1 and 32.1%, for erythromycin (ERY), 27.0, 28.7, 29.9% for cefuroxime (CEF), 28.3, 26.2, 27.3% for trimethoprim-sulfamethoxazole (SXT), 18.3, 14.4, 20.5% for tetracycline (TET) and 1.0, 1.7% and 1.6% for CTX. The incidence of MDR was 24.5% (318/1300) among SP from OT and IP combined. Of the FDA defined drugs considered, CTX was the least involved in the MDR phenotype, active against 97.8% of isolates. Against MDR SP, for other drugs considered resistance was 33.3% to TET, 55.5% R to PEN, 76.1% R to cefuroxime (CEF), 79.9% R to ERY, and 84.6% to SXT.

CONCLUSION:  Independent of patient-location, despite the high incidence of PEN and macrolide-resistance, greater than 98% of SP remain susceptible to CTX. Additionally CTX retains activity against greater than 97.0% of MDR SP compared to approx. 65% for ERY.

CLINICAL IMPLICATIONS:  After many years of clinical use, CTX retains its clinical utility despite widespread emergence of resistance and MDR in clinical isolates of SP.

DISCLOSURE:  M.E. Jones, None.

Tuesday, October 26, 2004

10:30 AM- 12:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543